Jump to content

Vincamine: Difference between revisions

Page 1
Page 2
Content deleted Content added
BogBot (talk | contribs)
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot
Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors. Alter: journal, title. Added s2cid. | Use this tool. Report bugs. | #UCB_Gadget
 
(80 intermediate revisions by 48 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{cs1 config|name-list-style=vanc}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 409095900
| verifiedrevid = 447608674
| IUPAC_name = (3α,14β,16α)-14,15-dihydro-<br>14-hydroxyeburnamenine-14-carboxylic acid methyl ester<br />OR<br />methyl (15''R'',17''S'',19''R'')-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.0<sup>2,7</sup>.0<sup>8,18</sup>.0<sup>15,19</sup>]nonadeca-2(7),3,5,8(18)-tetraene-17-carboxylate
| IUPAC_name = (3α,14β,16α)-14,15-Dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester<br />or<br />Methyl (15''R'',17''S'',19''R'')-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.0<sup>2,7</sup>.0<sup>8,18</sup>.0<sup>15,19</sup>]nonadeca-2(7),3,5,8(18)-tetraene-17-carboxylate
| image = Vincamine.svg
| image = (+)-Vincamine Structural Formula V2.svg
| width = 175


<!--Clinical data-->
<!--Clinical data-->
| tradename =
| tradename = Oxybral SR
| Drugs.com = {{drugs.com|international|vincamine}}
| Drugs.com = {{drugs.com|international|vincamine}}
| pregnancy_category =
| pregnancy_category =
| legal_status =
| legal_status =
| routes_of_administration =
| routes_of_administration = Oral


<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
Line 19: Line 23:


<!--Identifiers-->
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1617-90-9
| CAS_number = 1617-90-9
| ATC_prefix = C04
| ATC_prefix = C04
Line 25: Line 30:
| IUPHAR_ligand = 349
| IUPHAR_ligand = 349
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| DrugBank = DB13374
| UNII_Ref = {{fdacite|changed|FDA}}
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1165342
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 996XVD0JHT
| UNII = 996XVD0JHT
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08677
| KEGG = D08677
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 14635
| smiles = O=C(OC)[C@]3(O)n1c4c(c2ccccc12)CCN5CCC[C@](C3)(CC)[C@@H]45
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = RXPRRQLKFXBCSJ-GIVPXCGWSA-N


<!--Chemical data-->
<!--Chemical data-->
| C=21 | H=26 | N=2 | O=3
| C=21 | H=26 | N=2 | O=3
| molecular_weight = 354.44 g/mol
}}
}}


'''Vincamine''' is a peripheral [[vasodilator]] that increases blood flow to the brain (sold under the trademark '''Oxybral''') . It is an [[indole]] [[alkaloid]] (specifically a [[tryptamine]]) found in the leaves of ''[[Vinca minor]]'', comprising about 25-65% of the indole alkaloids found in ''Vinca minor'' by weight. It is also found in the species ''[[Catharanthus roseus]]''.{{Ref|Cook}} It can be synthesized from related alkaloids.{{Ref|Ullmann}}
'''Vincamine''' is a monoterpenoid [[indole alkaloid]] found in the leaves of ''[[Vinca minor]]'' (lesser periwinkle), comprising about 25–65% of its indole alkaloids by weight. It can also be [[organic synthesis|synthesized]] from related alkaloids.<ref>{{ cite encyclopedia | title = Indole Alkaloids | encyclopedia = Ullmann's Encyclopedia of Industrial Chemistry | edition = Fifth | page = 393 | publisher = Wiley-VCH | year = 1985 | isbn = 3-527-20100-9 }}</ref>


==Uses==
Vincamine is often used as a [[nootropic]] agent to combat the effects of aging, or in conjunction with other nootropics (such as [[piracetam]]) for a variety of purposes.
Vincamine is sold in Europe as a prescription medicine for the treatment of primary degenerative and vascular dementia.{{cn|date=July 2019}} In the United States, it is permitted to be sold as a dietary supplement when labeled for use in adults for six months or less.<ref>{{cite web | url = https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/vincamine_508.pdf | title = Summary of Data for Chemical Selection: Vincamine | work = National Toxicology Program | publisher = U.S. Department of Health and Human Services }}</ref> Most common preparations are in the [[sustained release]] tablet forms.

==Chemistry==
===Synthesis===
[[Tabersonine]] can be used for semi-synthesis of vincamine.<ref name = "Leeuwenberg_1985">{{cite journal|url=https://www.erowid.org/plants/voacanga_africana/voacanga_africana_info1.shtml|journal=Agricultural University Wageningen Papers|issn=0169-345X|volume=85|issue=3|year=1985|title=Voacanga, (Apocynaceae), a review of taxonomy, phytochemistry, ethnobotany and pharmacology| vauthors = Leeuwenberg AJ |author1-link=Anthonius Josephus Maria Leeuwenberg}}</ref>

===Derivatives===
[[Vinpocetine]] is a synthetic [[derivative (chemistry)|derivative]] of vincamine used for cerebrovascular diseases and as dietary supplement.<ref>{{Cite journal | url=https://www.fda.gov/Food/DietarySupplements/ProductsIngredients/ucm518478.htm |title = Vinpocetine in Dietary Supplements|journal = FDA|date = 2019-06-03}}</ref> Vincamine derivatives have been also studied as anti addictive<ref name="pmid31913038">{{cite journal |vauthors=Norwood VM, Brice-Tutt AC, Eans SO, Stacy HM, Shi G, Ratnayake R, Rocca JR, Abboud KA, Li C, Luesch H, McLaughlin JP, Huigens RW |title=Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity |journal=[[Journal of Medicinal Chemistry]] |volume=63 |issue=10 |pages=5119–5138 |date=May 2020 |pmid=31913038 |pmc=7324933 |doi=10.1021/acs.jmedchem.9b01924 |url= |issn=}}</ref> and antidiabetic<ref name="pmid31918073">{{cite journal |vauthors=Wang J, Lv X, Xu J, Liu X, Du T, Sun G, Chen J, Shen X, Wang J, Hu L |title=Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus |journal=[[European Journal of Medicinal Chemistry]] |volume=188 |issue= |pages=111976 |date=February 2020 |pmid=31918073 |doi=10.1016/j.ejmech.2019.111976 |s2cid=210133217 |url= |issn=}}</ref> agents.

==Research==
It may have [[nootropic]] effects.<ref name = "Leeuwenberg_1985" /> It has been investigated as novel anticancer drug.<ref name="pmid33450545">{{cite journal |vauthors=Al-Rashed S, Baker A, Ahmad SS, Syed A, Bahkali AH, Elgorban AM, Khan MS |title=Vincamine, a safe natural alkaloid, represents a novel anticancer agent |journal=[[Bioorganic Chemistry]] |volume=107 |issue= |pages=104626 |date=February 2021 |pmid=33450545 |doi=10.1016/j.bioorg.2021.104626 |s2cid=231624167 |url= |issn=}}</ref>

Concerns over long-term use have been documented by the US [[National Toxicology Program]].<ref>{{cite web
|title=Vincamine Dietary Supplements 1617-90-9 - National Toxicology Program|url=https://ntp.niehs.nih.gov/sites/default/files/ntp/htdocs/chem_background/exsumpdf/vincamine_508.pdf |website=National Institute of Environmental Health Sciences |access-date=4 December 2023}}</ref>

== See also ==
*[[Apparicine]]
*[[Conophylline]]


==References==
==References==
{{reflist}}
#{{Note|Cook}}{{cite journal
| doi = 10.1056/NEJM198112243052604
| author = Cook, P; James, I
| title = Cerebral vasodilators
| journal = N Engl J Med.
| volume = 305
| issue = 26
| pages = 1560–1564
| date = Dec. 24, 1981
| pmid = 7031468
}}
#{{Note|Ullmann}}{{cite encyclopedia
| title = Indole Alkaloids
| encyclopedia = Ullmann's Encyclopedia of Industrial Chemistry, Fifth Edition
| volume =
| pages = 393
| publisher = Wiley-VCH
| year = 1985
| id = ISBN 3-527-20100-9
| accessdate =
}}


==External links==
==External links==
* [http://www.mpbio.com/includes/msds/ansi/en/158295-en-ansi.pdf Vincamine MSDS]
* {{cite web | url = http://www.mpbio.com/includes/msds/ansi/en/158295-EN-ANSI.pdf | title = Vincamine MSDS | access-date = 2012-01-30 | archive-url = https://web.archive.org/web/20150608110220/http://www.mpbio.com/includes/msds/ansi/en/158295-EN-ANSI.pdf | archive-date = 2015-06-08 | url-status = dead }}
* {{cite web | url = https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/vincamine_508.pdf | work = Summary of Data for Chemical Selection | title = Vincamine - 1617-90-9 | author = Chemical Selection Working Group | publisher = NIH - United States National Institutes of Health | access-date = 2007-04-23 | archive-url = https://web.archive.org/web/20111021222436/http://ntp.niehs.nih.gov/ntp/htdocs/Chem_Background/ExSumPdf/Vincamine.pdf | archive-date = 2011-10-21 | url-status = live }}
* [http://ntp-server.niehs.nih.gov/ntp/htdocs/Chem_Background/ExSumPdf/Vincamine.pdf Vincamine article at NIH.gov]

==See also==
* [[Vinpocetine]]


{{Peripheral vasodilators}}
{{Peripheral vasodilators}}


[[Category:Carboxylate esters]]
[[Category:Tertiary alcohols]]
[[Category:Tryptamine alkaloids]]
[[Category:Methyl esters]]
[[Category:Methyl esters]]
[[Category:Alcohols]]
[[Category:Quinolizidine alkaloids]]
[[Category:Nitrogen heterocycles]]
[[Category:Vinca alkaloids]]
[[Category:Heterocyclic compounds with 5 rings]]

{{cardiovascular-drug-stub}}

[[de:Vincamin]]
[[es:Vincamina]]
[[pl:Winkamina]]
[[pt:Vincamina]]